Modifying cells to release exosomes overexpressing an RNA or a protein to enhance its natural therapeutic activity
Exosome generation
The ability to manufacture quantities of exosomes compatible with human use is a major challenge for the diffusion of this innovation. Indeed, the major hindrance to overcome for rendering exosome-based therapies clinically feasible is a cost-effective large-scale standardized production platform complying with regulatory issues and Good Manufacturing Practices (GMP).
Based on a patented and disruptive method to produce exosomes at high yield and large scale EVerZom is adressing this challenge and works towards the democratization of exosome-based-therapies. Our process that can be adapted to large scale boosts extracellular vesicle release by exerting a controlled mechanical stimulation on cells during their three-dimensional culture in a turbulent flow in bioreactors. This technology offers key advantages such as high yield production (10 times more vesicles in 1/10th of the time for mesenchymal stem cells (MSC)), large scale, GMP compatibility and shorter process.
During seeding or growing cellular phase, a gentle mixing homogeneously resuspends the beads. When we have reached the desired confluence on microcarriers (less than a week), we trigger a massive exosomes release (few hours) with a precise mechanical stimulation in a serum-free medium. To do this, we calculate the right micro-scale vortices that stimulate cells by Kolmogorov’s equation considering parameters like the geometry of the system, kinematic viscosity and the impeller rotation speed. All along the vesiculation protocol, we control that this shear stress does not damage the cells and monitor the quantity and size of exosomes released. The turbulence generated exosomes conserve the properties of their parental cells.
EVerZom platform is built on four blocks from the cell source to the formulated exosome drug
